Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials.
about
Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect ComparisonImplementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.
P2860
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Are post-docetaxel treatments ...... -analysis of published trials.
@en
Are post-docetaxel treatments ...... -analysis of published trials.
@nl
type
label
Are post-docetaxel treatments ...... -analysis of published trials.
@en
Are post-docetaxel treatments ...... -analysis of published trials.
@nl
prefLabel
Are post-docetaxel treatments ...... -analysis of published trials.
@en
Are post-docetaxel treatments ...... -analysis of published trials.
@nl
P2093
P2860
P50
P356
P1476
Are post-docetaxel treatments ...... a-analysis of published trials
@en
P2093
R Iacovelli
S Bracarda
P2860
P2888
P304
P356
10.1038/PCAN.2013.20
P577
2013-07-30T00:00:00Z